Association between maternal antidepressant use during pregnancy and the risk of autism spectrum disorder and attention deficit hyperactivity disorder in offspring
- PMID: 38762849
- DOI: 10.1007/s00787-024-02460-4
Association between maternal antidepressant use during pregnancy and the risk of autism spectrum disorder and attention deficit hyperactivity disorder in offspring
Abstract
Prenatal antidepressant exposure has been reported to be associated with adverse neurodevelopmental outcomes, yet studies considering confounding factors in Asian populations are lacking. This study utilized a nationwide data base in Taiwan, enrolling all liveborn children registered in the National Health Insurance system between 2004 and 2016. Subjects were divided into two groups: antidepressant-exposed (n = 55,707)) and antidepressant-unexposed group (n = 2,245,689). The effect of antidepressant exposure during different trimesters on autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) was examined. Sibling controls and parallel comparisons by paternal exposure status were treated as negative controls. Additional sensitivity analyses were conducted to examine the effects of antidepressant exposure before and after pregnancy. Prenatal antidepressant exposure was associated with increased risks of ASD and ADHD in population-wide and adjusted analysis. However when comparing antidepressant-exposed children with their unexposed siblings, no differences were found for ASD (Hazard ratio [HR]: 1.04, 95% confidence interval [CI] 0.76-1.42 in first trimester; HR: 0.96, 95% CI 0.62-1.50 in second trimester; HR: 0.69, 95% CI 0.32-1.48 in third trimester) and ADHD (HR: 0.98, 95%CI 0.84-1.15 in first trimester; HR: 0.91, 95% CI 0.73-1.14 in second trimester; HR: 0.79, 95% CI 0.54-1.16 in third trimester). Increased risks for ASD and ADHD were also noted in paternal control, before and after pregnancy analyses. These results imply that the association between prenatal antidepressant exposure and ASD and ADHD is not contributed to by an intrauterine medication effect but more likely to be accounted for by maternal depression, genetic, and potential environmental factors.
Keywords: Antidepressant exposure; Attention-deficit hyperactive disorder; Autism spectrum disorder; Cohort study; Neurodevelopmental outcomes; Pregnancy.
© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors have no competing interests or financial support to disclose. Ethical standards: This study was approved by the Research Ethics Committee of China Medical University and Hospital (approval number: CMUH108-REC1-142) and was executed as per the Declaration of Helsinki. The requirement for informed consent was waived.
References
-
- Woody CA et al (2017) A systematic review and meta-regression of the prevalence and incidence of perinatal depression. J Affect Disord 219:86–92. https://doi.org/10.1016/j.jad.2017.05.003 - DOI - PubMed
-
- Patkar AA, Bilal L, Masand PS (2004) Pharmacotherapy of depression in pregnancy. Ann Clin Psych 16(2):87–100. https://doi.org/10.1080/10401230490453662 - DOI
-
- Cohen LS et al (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295(5):499–507. https://doi.org/10.1001/jama.295.5.499 - DOI - PubMed
-
- Gelaye B, Rondon MB, Araya R, Williams MA (2016) Epidemiology of maternal depression, risk factors, and child outcomes in low-income and middle-income countries. Lancet Psychiatry 3(10):973–982. https://doi.org/10.1016/s2215-0366(16)30284-x - DOI - PubMed - PMC
-
- Gentile S (2017) Untreated depression during pregnancy: Short- and long-term effects in offspring. A systematic review. Neuroscience 342:154–166. https://doi.org/10.1016/j.neuroscience.2015.09.001 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
